Episodes

  • 68 - Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    68 - Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Jan 11 2026

    Discussão do artigo: "Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia" de Kantarjian H JCO 2024

    Apresentado por: Dr. Matheus Garcia

    Discussão por: Dr. Eduardo Burlamaqui , Dra. Ilana Barcessat, Dra. Amanda Chucre, Dr. Pedro Moraes e Dr. Vinícius Molla
    Show More Show Less
    33 mins
  • 67 - Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma

    67 - Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
    Jan 7 2026

    Discussão do artigo: "Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma" de Jagannath S JCO 2025

    Apresentado por: Dr. Guilherme Rodrigues

    Discussão por: Dr. Eduardo Burlamaqui, Dra. Ana Cecilia Bahia, Dr. Pedro Moraes e Dr. Vinícius Molla
    Show More Show Less
    24 mins
  • 66 - Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study

    66 - Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study
    Dec 30 2025

    Discussão do artigo: "Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study" de Chavez J blood 2025

    Apresentado por: Dra. Ilana Barcessat

    Discussão por: Dr. Rafael Faust , Dra. Ana Cecilia Bahia, Dr. Pedro Moraes e Dr. Vinícius Molla
    Show More Show Less
    27 mins
  • 65 - Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma

    65 - Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
    Nov 5 2025

    Discussão do artigo: "Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma" de Wang M JCO 2025

    Apresentado por: Dra. Ana Cecilia Bahia

    Discussão por: Dr. Gabriele Ritter, Dr. Matheus Garcia, Dr. Pedro Moraes e Dr. Vinícius Molla
    Show More Show Less
    34 mins
  • 64 - Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin

    64 - Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin
    Nov 2 2025

    Discussão do artigo: "Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin" de Curtis DJ NEJM 2025

    Apresentado por: Dr. Matheus Garcia

    Discussão por: Dr. Gabrielle Ritter, Dra. Lais Vianna, Dr. Wallber Moraes, Dr. Pedro Moraes e Dr. Vinícius Molla
    Show More Show Less
    39 mins
  • 63 - Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

    63 - Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT
    Sep 1 2025

    Discussão do artigo: "Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT" de DeFilipp Blood 2025

    Apresentado por: Dra. Amanda Chucre

    Discussão por: Dr. Eduardo Burlamaqui, Dr. Matheus Garcia, Dr. Pedro Moraes e Dr. Vinícius Molla
    Show More Show Less
    22 mins
  • 62 - Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation

    62 - Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation
    Aug 10 2025

    Discussão do artigo: "Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation" de Yao H JCO 2025

    Apresentado por: Dra. Ana Cecilia Bahia

    Discussão por: Dra. Amanda Chucre, Dra. Gabriele Ritter, Dr. Matheus Garcia, Dr. Pedro Moraes e Dr. Vinícius Molla
    Show More Show Less
    31 mins
  • 61 - Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study

    61 - Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study
    Aug 4 2025

    Discussão do artigo: "Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study" de Zeiser R JCO 2025

    Apresentado por: Dra. Amanda Chucre

    Discussão por: Dra. Ana Cecilia Bahia, Dra. Ilana Barcessat, Dr. Pedro Moraes e Dr. Vinícius Molla
    Show More Show Less
    22 mins